Clinical trials: Depression NOS
Major Depressive Disorder
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD).
- Trial name
- NCT06357832
- Testing
- Brainsway Deep TMS System
- Where
- 9 sites in United States, India and 1 more
- Volunteers
- 104 people
- Sponsor
- Brainsway
Bipolar Disorder
Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression
Evaluation of the impact of the genetic variation of individual genes on the therapeutic response and side effects profile in a cohort of well-characterized patients with bipolar depression, using NEUROPHARMAGEN.
- Trial name
- NCT04923204
- Testing
- Pharmacogenomic-testing with NEUROPHARMAGEN
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- AB Biotics, SA
Stress Disorders, Post-Traumatic, Anxiety Disorders
Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics
This is an observational study to assess the change in several psychological screening tools before and after a series of six ketamine infusions in paramedics who suffer from post traumatic stress disorder as a result of working…
- Trial name
- NCT03947099
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Klarisana Physician Services PLLC
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of LY2940094 in Major Depressive Disorder
The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of LY2940094 in healthy male subjects.
- Trial name
- NCT01263236
- Testing
- LY2940094
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- BlackThorn Therapeutics, Inc.
Depression Disorders, Anxiety Disorders
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive…
- Trial name
- SEQUOIA-3 (NCT07279038)
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Deliberate Solutions Inc.
Depression
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.
- Trial name
- NCT00949767
- Testing
- BMS-866949
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Depression
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. How duloxetine compares to escitalopram and placebo (an inactive ingredient)
- Trial name
- NCT00073411
- Testing
- duloxetine, escitalopram
- Where
- United States
- Volunteers
- 675 people
- Sponsor
- Eli Lilly and Company
Postpartum Depression
Efficacy of MI078 Capsules in Treating Postpartum Depression
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants.
- Trial name
- NCT06963580
- Testing
- MI078 capsule dose 1, MI078 capsule dose 2
- Where
- 21 sites in China
- Volunteers
- 72 people
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
Major Depressive Disorder
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
- Trial name
- NCT01371721
- Testing
- DVS SR
- Where
- 35 sites in United States, Mexico
- Volunteers
- 269 people
- Sponsor
- Pfizer
Bipolar Disorder, Depression, Bipolar
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood stabilizer is safe and effective in the short term treatment of Bipolar I Depression.
- Trial name
- NCT00483548
- Testing
- Ziprasidone
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 298 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Mental Health Issue, Mental Health Disorder
Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions
US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of two arms.
- Conditions
- Mental Health Issue, Mental Health Disorder, Mental Health, Depression
- Trial name
- NCT06190184
- Testing
- VIOME Precision Nutrition Program, Control arm
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Viome
Depressive Symptoms, Depression
Self-guided Treatment for Adolescents Navigating Depression
The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression.
- Conditions
- Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT05462652
- Testing
- Active Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder
Escitalopram in Adult Patients With Major Depressive Disorder
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression.
- Trial name
- NCT00668525
- Testing
- Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 877 people
- Sponsor
- Forest Laboratories
Depression, Depressive Disorder
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00366652
- Testing
- desvenlafaxine SR, desipramine, duloxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder (MDD)
Effects of Antidepressants on Sexual Functioning
The purpose of this trial is to study the effects of two depression medications on sexual functioning.
- Trial name
- NCT00051259
- Testing
- Extended-Release Bupropion Hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen